Haemonetics: CSL Plasma Improves The Outlook, Not The Entry Point (Rating Downgrade)

Haemonetics has received an improved outlook from CSL Plasma, but the entry point for the stock remains unchanged.

The company's stock price has risen in response to the news.

Haemonetics' plasma collection business has been performing well, but its manufacturing segment has faced some headwinds.